SUMMARY
The ocular motility disorder ''Congenital fibrosis of the extraocular muscles type 1'' (CFEOM1) results from heterozygous mutations altering the motor and third coiled-coil stalk of the anterograde kinesin, KIF21A. We demonstrate that Kif21a knockin mice harboring the most common human mutation develop CFEOM. The developing axons of the oculomotor nerve's superior division stall in the proximal nerve; the growth cones enlarge, extend excessive filopodia, and assume random trajectories. Inferior division axons reach the orbit but branch ectopically. We establish a gain-of-function mechanism and find that human motor or stalk mutations attenuate Kif21a autoinhibition, providing in vivo evidence for mammalian kinesin autoregulation. We identify Map1b as a Kif21a-interacting protein and report that Map1b À/À mice develop CFEOM. The interaction between Kif21a and Map1b is likely to play a critical role in the pathogenesis of CFEOM1 and highlights
INTRODUCTION
A subset of the 45 human kinesin motor proteins contributes to neuronal development and maintenance through cargo transportation and/or cytoskeletal regulation, and mutations in eight kinesins have been reported to cause neurological disorders. Among these, congenital fibrosis of the extraocular muscles type 1 (CFEOM1) results from a small number of recurrent and often de novo heterozygous mutations in the kinesin-4 family member, KIF21A (Yamada et al., 2003) . CFEOM1 is a disorder limited to congenital blepharoptosis (ptosis or drooping eyelids) and restricted eye movements. Vertical movements are markedly limited and neither eye can be elevated above the midline, while horizontal movements vary from full to none. Aberrant residual eye movements are common, supporting errors in extraocular muscle (EOM) innervation (Engle et al., 1997; Yamada et al., 2003) .
KIF21A is composed of an amino terminal motor domain, a central stalk domain, and a carboxy terminal domain containing WD40 repeats. Twelve heterozygous missense and one heterozygous single amino acid deletion account for all KIF21A mutations among the 106 unrelated CFEOM1 probands reported to date (Chan et al., 2007; Lu et al., 2008; Wang et al., 2011) . The mutations alter six amino acid residues in the third coiledcoil region of the stalk and two residues in the motor domain and result in indistinguishable phenotypes that are limited to ptosis and ocular dysmotility (Demer et al., 2005; Yamada et al., 2003) . Mapping the mutations to the Kif21a primary and the three-dimensional motor structures highlight the clustering of 11 mutations in the third coiled-coil stalk domain, while two mutations map close to one another in loop 1 and helix a6 on the lateral surface of the highly conserved motor domain, a region of unknown function far from the kinesin motor nucleotide-binding pocket and the microtubule-binding domain (Figures 1A and S1A available online) .
Kif21a is an anterograde ATP-dependent motor protein (Marszalek et al., 1999) that interacts in vitro with Kank1, a regulator of actin polymerization (Kakinuma and Kiyama, 2009 ). The interaction of Kif21a with the Kank1/LL5B complex at the cell cortex stabilizes microtubule dynamics in vitro (van der Vaart et al., 2013) . Human and mouse KIF21A/Kif21a is expressed widely in vivo and is present in the cell body, axons, and dendrites of most neuronal populations including cranial motor neurons, as well as in EOM and skeletal muscles, from early development into adulthood (Desai et al., 2012) . The spatial expression of KIF21A does not appear altered in individuals with CFEOM1 (Desai et al., 2012) . Thus, the neurobiology of CFEOM1 and how human Kif21a mutations cause this very circumscribed developmental disorder remain unclear.
In this study, we generated Kif21a knockin and knockout mouse models to define the CFEOM1 disease etiology, and demonstrate that CFEOM1 mutations act through a gain-offunction mechanism to attenuate Kif21a autoinhibition. We find that mutant hyperactive Kif21a causes thinning of the distal oculomotor (OMN) nerve with hypoplasia of the superior division (OMNsd) and aberrant branching of the inferior division (OMNid). Stalled proximal OMNsd axons have turning defects, with 
RESULTS
Kif21a R954W Knockin Mice Recapitulate Human CFEOM1 Human KIF21A and mouse Kif21a proteins are 93% homologous, and all residues altered by CFEOM1 mutations are conserved between the two species ( Figure 1B) . Moreover, 74% of probands harbor the specific R954W substitution, while 89% harbor mutations that alter residue R954. Thus, to study the pathogenesis of CFEOM1, we introduced a 2,827C/T mutation into the endogenous mouse Kif21a locus, generating Kif21a knockin mice harboring R943W (Kif21a KI ), the equivalent of the human R954W substitution (Figures S1B-S1D EOMs are innervated by the paired OMN, trochlear, and abducens cranial nerves ( Figure S1E ). The OMN nerve divides just prior to entering the orbit, with the larger OMNid innervating the medial rectus (MR), inferior rectus (IR), and inferior oblique (IO) muscles and the ciliary ganglion, and the smaller OMNsd innervating the superior rectus (SR) and the levator palpebrae superioris (LPS) muscles. Postmortem pathology of an adult with CFEOM1 (Engle et al., 1997) resulting from the R954W KIF21A amino acid substitution (Yamada et al., 2003) revealed hypoplasia of the SR and LPS EOMs that elevate the eye and eyelid, respectively, and absence of the OMNsd and corresponding somatic motor neurons ( Figure S1E ). The OMNid and the abducens nerve were also thin, and the EOMs they innervated had nonspecific changes. Similar orbital changes were documented by MRI of individuals with CFEOM1 and motor or stalk mutations (Demer et al., 2005 axons proximal to the bulb had straight trajectories similar to WT. Within the bulb, a subset of axons pursued complex trajectories and appeared to terminate, while others maintained straight trajectories and exited the bulb to form the thin distal nerve.
We employed ex vivo anterograde and retrograde tracer studies to identify the axon population terminating within the bulb ( Figures S2G-S2N ). The bulb was detected by anterograde lipophilic dye labeling ( Figures S2O and S2P) , and we took advantage of the normal contralateral innervation pattern of the OMNsd to label OMNsd axons versus both OMNsd and OMNid axons using two dye colors ( Figures 2O-2T ). Two-color labeling revealed that the prematurely terminating axons were primarily those of the OMNsd, which originated from the :GFP (D, F, and H) embryos at E10.5 (C and D), E12.5 (E and F), and E13.5 (G and H); n = 5, 5 for each age. Note the normal appearance of mutant III and IV nuclei and exiting nerves. At E12.5 and E13.5, mutant III nerve is thickened following exit into the periphery compared to WT (F and H, arrows) . Scale bar represents 100 mm. :GFP embryos to visualize their complete trajectories. While the trochlear nerve appeared normal, the distal OMN and abducens nerves appeared thin (Figures 3A and 3B) , consistent with the loss of OMN and, to a lesser degree, abducens motor neurons in the mature animals. Moreover, the images confirmed proximal thickening, bulb formation, and distal thinning of the Kif21a KI/KI OMN nerve and revealed hypoplasia of its developing distal OMNsd. The thin OMNsd was confirmed in an E14.5 Kif21a +IKI embryo by two-photon microscopy and three-dimensional reconstruction (Movies S1
and S2), consistent with its absence in the human CFEOM1 autopsy study (Engle et al., 1997) . Next, OMN nerves were dissected from E11.5-E15.5 embryos to define the normal and abnormal development of the distal superior and inferior branches ( Figures 3C-3J ). Visualizing the distal aspect of the nerve, we found that WT axons paused and followed complex trajectories prior to forming branches to innervate target EOM. This behavior is consistent with developing axonal populations arriving at ''decision regions'' to turn or to enter a target in vivo, as documented in growth cones of chick spinal motor neurons within the plexus (Tosney and Landmesser, 1985) , retinal ganglion cell at the optic chiasm (Mason and Erskine, 2000) , and cortical neurons within the corpus callosum (Kalil et al., 2000) . In mutants, the developing OMNsd was markedly thinner than that of WT nerves at all ages, while the OMNid appeared moderately thinner, with premature fasciculation into transient aberrant branches. At E15.5, the mutant abducens nerve was thinner while the trochlear appeared similar to wild-type.
Kif21a
KI/KI Oculomotor Nerve Pathology Does Not Arise from a Primary Defect in EOM Development, Axon Retraction, or Motor Neuron Cell Death Next, we asked whether the OMN pathology in Kif21a KI/KI mice, which begins prior to E12.5, could result from a primary defect in EOM development. We found, however, that while Kif21a .5 (E and F), E13.5 (G and H), and E15.5 (I and J); n = 10, 10 for each age. At E11.5, both WT and mutant nerves reach the orbit and appear to explore the local environment, but mutants have fewer exploring axons within the distal decision region (C and D). At E12.5, a small, defasciculated Sd protrudes from the WT nerve, and the Id exhibits an enlarged distal region with a subset of axons pursuing convoluted trajectories (E). In contrast, the E12.5 mutant nerve (F) has thinner Sd and Id, and several aberrant, fasciculated branches (arrows) emerge from the Id exploratory region. At E13.5, the WT nerve (G) has a more substantial Sd with several fasciculated bundles, while the mutant (H) Sd is thin or absent, and the Id exploratory region is small and has aberrant branches (arrow) as well as the normal branch to the IO. At E15.5, WT III (I) appears fully developed, with Sd branches to the SR and LPS. The Id now sends off several branches, presumably to the MR, IR, and IO. In comparison, mutant III (J) Sd is severely hypoplastic, while the Id is thin but sends off several stereotyped branches similar to WT, with no visible aberrant branches. Compared to WT, mutant VI was also hypoplastic compared to WT (arrow head), while mutant IV appeared normal.
(K) Onset of Kif21a expression in EOMs during development. Immunostaining with anti-Kif21a antibody (red) and anti-Myo antibody (green) on coronal sections through the eye of E12.5, E13.5, and E14.5 WT mice. Kif21a is detected in the retina and in rootlets of many developing nerves (including III and VI, arrowheads) but is absent from green EOMs (arrows) until E14.5, subsequent to its neuronal expression. expression in OMN neurons begins at E10 (Desai et al., 2012) , expression in EOM began at E14.5 ( Figure 3K ), several days after the nerve pathology. We also found the position and size of the SR and LPS muscles appeared normal at E14.5 ( Figure 3L ) and that EOM hypoplasia began after P0, several days after EOM innervation was reduced ( Figures 1L-1Q ).
To confirm that the OMN bulb resulted from premature axon termination rather than axon retraction, we measured proximal and distal OMN nerve diameters in WT and mutant embryos at E10.5, E11.5, and E12.5 ( Figures 3M-3S ). The proximal diameter of the WT nerve at E10.5 was approximately twice that of its distal diameter, while by E11.5 there was no significant difference between them, probably reflecting the growth of additional axons along the WT nerve between E10.5 and E11.5. Neither proximal nor distal diameter of the mutant nerve differed significantly from WT at E10.5. In contrast to WT, however, the mutant proximal diameter increased significantly over time, while the distal diameter did not, resulting in distal nerve thinning. This is consistent with a reduction in axon growth down the mutant nerve compared to WT after E10.5.
We To examine the ultrastructure of the mutant bulb, we examined E12.5 nerves from two mutant mice in cross-section at levels within and just proximal and distal to the bulb and compared to nerves from two WT mice at equivalent proximal and distal cross-sectional levels ( Figures 4A-4E ). Compared to the crosssectional area of the proximal mutant nerve prior the bulb, the area within the bulb was increased 3.5-to 4-fold, while the area distal to the bulb was decreased 3-fold ( Figure S3A ), consistent with mutant OMN nerve distal thinning. For each of the five cross-sections ( Figures 4A-4E ), we counted and measured all objects and labeled them as axons cut in cross-section, axons cut longitudinally or obliquely, central growth cones, lamellipodia/filopodia, or degenerating axons ( Figures 4F-4I , S3B, and S3C). Proximal and distal sections of both WT and mutant nerves consisted primarily of axons running parallel to the nerve trajectory, with a small number of moderatesized growth cones and lamellipodia/filopodia (Figures 4F-4I) . WT nerves contained similar numbers of axons, and axon number did not vary greatly between proximal and distal levels. In contrast, the mutant nerves' distal sections contained 55% fewer axons than proximal sections, and the proximal sections contained 18% fewer axons than WT proximal sections ( Figures  4N and S3D) . The moderate reduction in mutant nerve proximal axons probably reflects pathologic cell death in the E12.5 Kif21a KI/KI OMN nucleus (refer to Figures 3T and 3U) , while the much greater reduction in mutant nerve distal axons is consistent with axon termination in the bulb.
To determine whether CFEOM1 mutations visibly alter the distribution of organelles, we examined proximal nerve sections, as these included cross-sectional axons of the OMNsd destined to stall as well as OMNid axons destined to pass through the bulb ( Figure S3B ). We found no difference in the average densities of vesicles, membranes, or mitochondria between mutant and WT axons ( Figures S3E and S3F ). These data support absence of a general disruption of axonal trafficking.
We examined bulb ultrastructure and found it to be highly disorganized, with many axons running perpendicular to the cross-sectional plane ( Figures 4J-4M ). Moreover, there was a remarkable increase in growth cone size and in number of filopodia and degenerating axons ( Figures 4N, 4O, S3D , and S3G). These findings are again reminiscent of normal decision regions in which populations of axons change direction. Within such regions, growth cones cease forward movement, enlarge, extend multiple filopodia, and develop erratic-appearing trajectories prior to establishing the correct new direction of growth (Mason and Erskine, 2000) . Taken together, our results suggest a model in which WT OMNsd axons normally reach the distal nerve, where they pause and explore the environment and then turn and fasciculate as its superior branch. In contrast, in the CFEOM1 disease state, our data suggest that these axons stall within the proximal nerve, where they explore the environment within the bulb region, fail to form an aberrant OMNsd, and then degenerate.
The Kif21a KI/KI CFEOM1 Phenotype Results from a Gainof-Function Mechanism All reported CFEOM1 mutations are heterozygous, result in a single amino acid substitution or deletion in the motor or third coiled-coil stalk of KIF21A ( Figure 1A ), and cause indistinguishable human phenotypes. These genetic data strongly support altered KIF21A function underlying CFEOM1. We previously noted, however, that the level of R954W mutant KIF21A protein in human CFEOM1 postmortem brain tissue lysates was reduced (Desai et al., 2012) . Thus, we asked whether loss of KIF21A function caused CFEOM1. We examined Kif21a KI/KI brain lysates and found, similar to the human autopsy, that Kif21a protein levels were reduced 35%, 45%, and 60% compared to WT in E13.5, E18.5, and adult mice, respectively ( Figure S4A ), while Kif21a mRNA levels did not differ (Figures S4B and S4C) . Thus, Kif21a mutant protein level appears highest during the embryonic period when CFEOM1 pathology occurs. To determine whether the reduction of Kif21a protein in Kif21a KI/KI mice contributed to the CFEOM1 phenotype, we generated Kif21a knockout mice by deleting much of the motor domain ( Figures S4D-S4G ). The resulting homozygous mice completely lacked full-length (FL) Kif21a and harbored a very low level of a truncated Kif21a (Figure S4F) Figure 5M ). These data suggest that the mouse is protected against CFEOM1 by reduced numbers of Kif21a dimers containing one or two mutant proteins. Thus, CFEOM1 penetrance correlates with the absolute amount of mutant Kif21a protein and is embryos at E13.5 (n = 6, 6, 29 ± 2 versus 30 ± 2; mean ± SD; p = 0.206) and E14.5 (n = 6, 6, 48 ± 3 versus 46 ± 2; mean ± SD; p = 0.334).
(L) Representative western blot analysis of Kif21a protein levels in E18.5 brain tissues corresponding to genotypes in allelic series (n = 4 To determine whether other CFEOM1 mutations and various Kif21a truncations would also enhance association of Kif21a with the microtubule cytoskeleton, we generated a series of Kif21a FL and truncated constructs ( Figure 5P ) into which we introduced one of the motor domain substitutions (MT1, M356T in both human and mouse) and two of the third coiledcoil domain substitutions (MT2 and MT3, human M947I and R954W corresponding to mouse M936I and R943W, respectively). We confirmed that both FL WT and mutant Kif21a formed homodimers, and the amount of dimerized protein did not differ between them ( Figure S5A ). We then overexpressed the truncation and FL mutant constructs in HEK293 cells and cosedimented Kif21a and polymerized microtubules from each cell lysate. Significantly more WT or MT1 stalk-truncated, as well as FL MT1, MT2, and MT3, mutant constructs were associated with the microtubule fraction compared to FL WT Kif21a ( Figures  6A and 6B) . Moreover, the increased association of the WT and MT1 truncation was indistinguishable. These changes in microtubule association were also directly visualized following overexpression of the constructs in HeLa cells (Figures S5B-S5E) .
The indistinguishable CFEOM1 phenotypes in humans (Demer et al., 2005; Yamada et al., 2003) and the increased Kif21a-microtubule association resulting from substitutions within either the KIF21A motor or third coiled-coil domain led us to search for a single disease mechanism specific to these domains. Several kinesins have been demonstrated in vitro to autoregulate their activity by folding within a stalk linker region and stabilizing the folded conformation through intramolecular interactions (reviewed in Verhey and Hammond, 2009 ). Thus, we asked whether WT Kif21a is similarly autoregulated, and whether CFEOM1 mutations alter KIF21A autoinhibition. We performed coimmunoprecipitation and found that the motor domain interacted only with the third coiled-coil domain ( Figures 6C, 6D , and S5F). To determine whether this interaction regulated Kif21a function, we performed in vitro single-molecule fluorescence imaging assays using total internal reflection (TIRF) microscopy. In BRB80 buffer, few WT FL Kif21a bound to microtubules and moved processively, consistent with Kif21a existing primarily in an autoinhibited state ( Figure 6E ; Movie S3). In contrast, both WT and MT1 mutant Kif21a truncated prior to the third coiled-coil domain showed a significant increase in the number of active (land-and-run) landing events ( Figures 6F,  6G , and 6K; Movies S4 and S5). Moreover, there was no significant difference between the WT and MT1 truncation constructs, demonstrating that CFEOM1 motor mutations do not directly alter the ATP enzymatic activity or microtubule-binding motif. We then tested whether purified WT third coiled-coil domain protein could block the microtubule-binding activity of the truncation construct. Indeed, WT-truncated Kif21a active landing events were dramatically inhibited with the introduction of WT third coiled-coil domain in trans (Figures 6H and 6K ; Movie S6).
Next, we asked whether CFEOM1 mutations alter Kif21a autoinhibition. We found that the interaction of the motor and third coiled-coil was attenuated by the introduction of the MT1-motor or the MT2-or MT3-stalk mutations ( Figures 6C,  6D , S5F, and S5G). We repeated the single-molecule experiment combining either WT truncation with purified MT3 mutant third coiled-coil protein or MT1 mutant truncation with WT third coiled-coil protein in trans. As predicted, both combinations failed to fully block the active landing events of truncated Kif21a (Figures 6I-6K and S5H; Movies S7 and S8). Moreover, introduction of the mutant constructs increased the ratio of active versus inactive (dead motor) landing events compared to WT ( Figure S5I ).
Lastly, we asked how CFEOM1 mutations alter FL Kif21a microtubule association and motile properties. While an increase in the frequency of active landing events of mutant Kif21a was evident in BRB80 buffer, run lengths were too short for accurate measurement ( Figures S5J and S5K) . Thus, we used BRB30, a lower ionic strength buffer that permitted quantification of both landing and motile properties. In contrast to FL WT Kif21a, both FL MT1-and MT3-Kif21a had a 10-fold increase in the frequency of active landing events (Figures 6L-6O ; Movie S9), while also decreasing the percentage of inactive landing events or dead motors ( Figure S5L ). We measured velocities and run lengths of active motors for all three FL constructs and found no significant differences between them ( Figure 6P) .
Collectively, these data establish that Kif21a adopts an autoinhibited state through the direct and specific interaction of its motor and third coiled-coil stalk domains and reveal that this stalk-induced autoinhibition is partially released by CEFOM1 mutations, enhancing the association of Kif21a motors with (P) Names and corresponding schematics of the FL and truncated Kif21a constructs. Kif21a domains are noted above the top left construct. Constructs containing mutant amino acid residues corresponding to MT1, MT2, or MT3 have the amino acid substitution represented in red font. Construct code names begin or end with the tag designation: ''G-'' at the start denotes an N-terminal GFP tag, while ''-G,'' ''-mCh,'' or ''-M'' at the end denote a C-terminal GFP, mCherry, or Myc tag, respectively; ''m'' or ''h'' prior to the parenthesis denotes mouse or human construct, respectively; the number within the parentheses denotes the amino acid residues contained in the construct and is followed by MT1, MT2, or MT3 if the construct contains a CFEOM1 amino acid substitution. Mouse and human constructs have slightly different amino acid numbering. See also Figure S4 . (legend continued on next page) microtubules for productive movement without altering the motor's velocity and run length. Collectively, these data confirm and expand recently published in vitro data (van der Vaart et al., 2013) . We also provide in vivo evidence of attenuated autoinhibition by CFEOM1-Kif21a motor and stalk mutations.
KI cultures. There were no significant differences in overall growth characteristics or percent of axons with collapsed growth cones ( Figures 7A-7F ). We next examined the OMN growth cones by immunohistochemistry in fixed explants cultured for 18 hr. We found a moderate but significant increase in both growth cone area and number of filopodia per growth cone in Kif21a KI/KI explants compared to WT (Figures 7G-7I ). Kif21a is recruited by Kank1 to the cell cortex in vitro (van der Vaart et al., 2013) , and overexpressed CFEOM1 mutant KIF21A enhances Kif21a-Kank1 interaction in vitro (Kakinuma and Kiyama, 2009 ). Thus, we compared (O and P) Quantification of mouse WT FL or mutant (MT3 and MT1) FL Kif21a on microtubules for 10 min in BRB30 motility buffer reveals a significant increase in landing frequencies (O) of MT3 and MT1 mutant FL Kif21a compared to WT, but no significant changes in velocity or run length (P). For each construct in (K), (O), and (P), data were acquired from two independent experiments, and from three time-lapsed images for each experiment. Frequency: mean ± SEM, velocity: mean ± SD, run length: mean ± SEM. *p < 0.05, **p < 0.01, ns, not significant. Constructs are per Figure 5P . See also Figure S5 and Movies S3, S4, S5, S6, S7, S8, and S9. the fluorescent intensity ratio in the OMN growth cone versus cell body of both Kif21a and Kank1 but found no differences in either ratio between WT and Kif21a KI/KI explants ( Figures S6A-S6D ).
These data support mild attenuation but not complete ablation of Kif21a autoinhibition. Moreover, while enlarged growth cones with increased numbers of filopodia in vitro probably share a common pathogenesis with bulb formation by mutant OMN axons in vivo, the in vitro phenotype is much milder, supporting an important environmental contribution to the development of CFEOM. CFEOM3-causing TUBB3 missense mutations stabilize yeast microtubules and alter Kif21a-microtubule interactions (Tischfield et al., 2010) . Thus, we asked whether we could detect a difference in microtubule plus-end behavior by tracking EB3 protein following overexpression of WT versus mutant Kif21a in COS7 cells. Although WT Kif21a decreased microtubule polymerization rate and microtubule dynamics slightly but significantly compared to the control, consistent with recently reported data (van der Vaart et al., 2013), we did not detect a significant difference between the behavior of WT and CFEOM1 mutant Kif21a ( Figures S6E-S6H ).
Endogenous Kif21a and MAP1B Interact, and Map1b
-/-Mice Have CFEOM To identify additional Kif21a-interacting partners that could play a role in the pathogenesis of CFEOM1, we immunoprecipitated E18.5 WT brain lysates with IgG and with three different antiKif21a antibodies, each of which recognized a distinct region of the Kif21a protein, and then performed mass spectrometry (data not shown). One consensus candidate we identified was the microtubule-associated protein 1b (Map1b) heavy chain, a major cytoskeletal protein essential for axon development in vivo. There are intriguing similarities between loss of Map1b function and our Kif21a KI/KI data. Loss of Map1b impairs growth cone turning in vitro and axon guidance in vivo (Bouquet et al., 2004; Mack et al., 2000; Meixner et al., 2000) . Cultured Map1b À/À neurons have increased growth cone area and number of filopodia and altered microtubule dynamics with longer pauses and fewer catastrophes (Gonzalez-Billault et al., 2002; Tortosa et al., 2013; Tymanskyj et al., 2012) . Finally, the eyes of Map1b À/À mouse models are reported to appear ptotic and retracted (Meixner et al., 2000; Takei et al., 1997; Edelmann et al., 1996) . To explore a potential role of Map1b in CFEOM1, we confirmed the interaction of Map1b with WT Kif21a in E18.5 brain tissue lysates and then determined that endogenous WT and CFEOM1 mutant Kif21a interacted equally well with Map1b by coimmunoprecipitation ( Figure 8A) . A GST pulldown assay demonstrated that Kif21a interacted with Map1b through its third coiled-coil stalk and WD40 domains (Figure 8B) 
DISCUSSION
Since first described in the late 1800s (Heuck, 1879) , the etiology of CFEOM1 has been unknown, and whether it was primarily neuropathic or myogenic remained unclear. By introducing the most common CFEOM1 KIF21A missense mutation into mice, we recapitulate the human phenotype in both heterozygous and homozygous states. Analysis of Kif21a KI mice reveals that the CFEOM1 phenotypes of ptosis and restricted upgaze reflect failure of LPS and SR innervation secondary to developmental stalling of their growing OMNsd axons, while variably restricted and aberrant horizontal movements probably result from more subtle errors in innervation of the OMNid muscles. These studies establish a neurogenic etiology for CFEOM1. Kinesin motor proteins are important for many aspects of neuronal development, and it is presumed that their activities need to be tightly regulated. Our data confirm that Kif21a can adopt a preferred autoinhibited state that requires the interaction of the lateral motor and third coiled-coil stalk domains and an active state in which this interaction has been released and Kif21a binds to the microtubule. CFEOM1 mutations attenuate Kif21a autoinhibition by disrupting this interaction, enhancing Kif21a association with microtubules without altering velocity or run length. This provides a single unifying molecular mechanism for both motor and stalk mutations to account for the indistinguishable human phenotypes.
While perturbed kinesin autoinhibition in worm, fungus, and fly in vivo are reported to cause loss-of-function phenotypes (Imanishi et al., 2006; Moua et al., 2011; Seiler et al., 2000) , we find that loss of KIF21A function does not cause CFEOM1, and attenuated Kif21a autoinhibition resulting from CFEOM1 mutations does not result in the Kif21a null phenotype. Together, our data support gain-of-function mutations underlying CFEOM1 and suggest that both homozygous and heterozygous mutant dimers can disrupt Kif21a autoinhibition. Notably, while most human mutations in other kinesins cause partial or complete loss of function, mutations in KIF22 and KIF5A highlight specific residues that could prove important for autoregulation (Boyden et al., 2011; Crimella et al., 2012) . Thus, pathological alterations of autoinhibition may extend beyond KIF21A and represent a more generalized mechanism underlying disorders of kinesin function.
Despite the broad expression of Kif21a (Desai et al., 2012 ) and its attenuated autoinhibition by CFEOM1 mutations both in vivo and in vitro, it is intriguing that these mutations selectively target ocular motor neuron development. These vulnerable OMN axons appear to form a pathological decision region defined by stalled axons with enlarged growth cones and turning defects, similar to the behavior of WT OMN axons when they enter a distal decision region near the orbit, as well for other axon populations within decision regions for turning (Mason and Erskine, 2000 turning behavior and enlarged growth cones in Map1b À/À neurons (Bouquet et al., 2004; Gonzalez-Billault et al., 2002; Mack et al., 2000; Tortosa et al., 2013) . Moreover, both Map1b and Kif21a can regulate microtubule dynamics in neuronal growth cones (Tortosa et al., 2013; Tymanskyj et al., 2012; van der Vaart et al., 2013) . Thus, the interaction between these two proteins is likely to play a critical role in the pathogenesis of CFEOM1. Combined with our previous reports of CFEOM3 arising from mutations in either TUBB3 or TUBB2B (Cederquist et al., 2012; Tischfield et al., 2010) , these data highlight a selective vulnerability of the developing OMN nerve to perturbations of the axon cytoskeleton.
EXPERIMENTAL PROCEDURES
Detailed procedures are described in the Supplemental Experimental Procedures. (Lewcock et al., 2007) or Thy1:GFP reporter mice (Jackson Laboratory) and studied following a minimum of four backcrosses to 129S1. All animal work was performed in compliance with Boston Children's Hospital IACUC Protocols.
Transgenic Mice
Embryo Dissection, Immunohistochemistry, and Ultrastructural Analysis Briefly, for immunohistochemistry, embryos and adult mice were dissected and fixed in 4% PFA. After blocking with serum, whole embryos or dissected tissues were sequentially incubated with primary and secondary antibodies. For ultrastructural analysis, embryos were fixed in 2% paraformaldehyde, 2.5% glutaraldehyde, 0.02% CaCl2, and 2% tannic acid in 0.1 M cacodylate buffer at room temperature, and a tissue block containing the OMN nerve was prepared for electron microscopy.
Anterograde and Retrograde Labeling
Anterograde and retrograde labeling of E14.5 and P0 ocular cranial nerves and EOMs were performed by placing NeuroVue Maroon (red) or Jade (green) dye (MTTI)-soaked filter strips at specific axial levels of the brainstem or orbit. After dye diffusion, brainstems or orbits were observed for successful dye placement and completely labeled samples were prepared for confocal microscopy. Consecutive scans and stacks of images through the nerve and/or each nucleus were collected using a laser-scanning confocal microscope.
Microtubule Cosedimentation Assay
Microtubule cosedimentation assay was performed as described previously (Tischfield et al., 2010) with modifications detailed in the Supplemental Experimental Procedures. Clarified lysates in BRB80 buffer of E18.5 WT and mutant brains or HEK293 cells overexpressing WT or mutant Kif21a constructs were incubated with polymerized microtubules, palitaxol, and AMP-PNP or ATP at 37 C, centrifuged at 55,000 rpm at 25 C, and then subjected to SDS-PAGE and western blot.
Coimmunoprecipitation, Protein Purification, and GST Pull-Down Clarified lysates in lysate buffer (50 mM TrisHCl, 150 mM NaCl, 1 mM EDTA, 1% NP40 [pH 6.8]) of E18.5 WT and mutant brains or HEK293 cells overexpressing WT or mutant Kif21a constructs were incubated with antibody and protein-G agarose beads with gentle rotation at 4 C overnight. After washing with lysate buffer, denatured elutions were subjected to SDS-PAGE and western blot. For GST pull-down, GST-fused proteins were expressed and purified from E. Coli BL21 cells with glutathione sepharose beads. Clarified lysates (as described above) were incubated with protein-bounded beads at 4 C for 4 hr.
The final denatured elutions were subjected to SDS-PAGE and western blot. For in vitro single-molecule motility assays described below, thrombin was used to cleave off the GST tag.
In Vitro Single-Molecule Motility Assays Single-molecule assays of GFP-fused WT or mutant Kif21a constructs were performed in motility chambers as previously described (Qiu et al., 2012) . Coverslips were sequentially coated with 1 mg/ml biotin-BSA and 0.5 mg/ml streptavidin to immobilize Taxol-stabilized Cy5 microtubules. Clarified cell lysates containing equal amounts of protein were diluted in motility buffer and added to the chamber. Images were recorded every 2 s for 5 or 10 min using an Olympus IX-81 TIRF microscope. 
